Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients

COVID-19 by SARS-CoV-2 Infection Clinical Trial

Official title:

Prevalence and Clinical Evolution of Olfactory and Taste Disorders in Patients Infected by SARS-CoV-2

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04361565
• Other study ID #: 20odontocovid01
• Status: Enrolling by invitation
• Start date: March 20, 2020
• Est. completion date: May 31, 2020

Study information

• Verified date: April 2020
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A novel coronavirus SARS-CoV-2 HAS arose in 2019 in Wuhan, China. Beside the classical semiology of this infection, numerous patients described olfactory and teste disorders. These symptoms are not described in this coronavirus, neurotropism of coronaviridae has been documented before. The aim of the study is to evaluate prevalence of anosmia and dysgeusia (olfactory and taste disorders) in coronavirus diagnosed patients and compare with different clinical conditions. The second endpoint is to evaluate the duration of these symptoms in order to better understand the semiology of this infection.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 50
• Est. completion date: May 31, 2020
• Est. primary completion date: April 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• COVID-19 diagnosed

Related Conditions & MeSH terms

• COVID-19 by SARS-CoV-2 Infection
• Taste Disorders

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Anosmia	Prevalence for anosmia in the COVID-19 + patients	45 days
Primary	Ageusia	Prevalence for ageusia in the COVID-19 + patients	45 days
Primary	Duration of the loss of anosmia ageusia	Duration measured in days	45 days